Event info
Date:23 Mar
Time:17:00 - 20:00
Venue:Medicon Valley Alliance, Copenhagen

POSTPONED – MVA Oncology Network meeting

 

Welcome to the MVA Oncology Network and our 9th meeting!
The future of oncology – treatments in multiple combinations.

Combination therapies are upcoming within oncology R&D, but what is the right strategy for their development in the early stages? At this meeting we will look into the optimal design of early clinical trials, the challenges of value and pricing-setting of combination treatments, and get more insight in the patient experience.  

Medicon Valley Alliance, together with one of our members – AbbVie – welcomes you to the MVA Oncology Network and our 9th meeting where we will discuss the future of oncology – treatments in multiple combinations. The meeting format will include presentations and a panel discussion, so all can actively engage.

Date:

23 March, 2020

Time:

17:00 – 20:00

Host:

AbbVie

Venue:

Auditorium Medicon Valley Alliance, Edvard Thomsens vej 8-14, DK-2300 Copenhagen S, Danmark

Cost:

Free of charge for MVA members

Deadline: 

18 March, 2020

 

In the light of the most recent recommendations from the Danish and Swedish health authorities we have decided to postpone this meeting. Please consult this page for updates. Already registered participants will get notified.

The network
MVA Oncology Network is a professional and social network for professors, PIs and corporate level executives from the regional oncology eco-system. The network focuses on best practice, experience and current challenges for public-private collaboration and the commercialization of oncology related R&D in the Medicon Valley region.

Joining the network is free of charge and is limited to Medicon Valley Alliance members only. However, non-member organizations and companies are welcome to attend one network event to evaluate if joining the network is relevant. If so, becoming a member of Medicon Valley Alliance will automatically allow you to join the oncology network.

Program

Moderator: Linn Mandahl, General Manager, AbbVie Scandinavia

17:00-17:30 

Registration, networking and a bite to eat – meet the fellow participants

17:30-17:35 

Welcome 
Linn Mandahl, General Manager, AbbVie Scandinavia

17:35-17:40 

Sponsored pitch 

Where is the IP in combination treatment?
Jens Viktor Nørgaard, Partner, European Patent Attorney, HØIBERG

17:40-18:20

“Who are we?” 4 x 10 minute corporate/academic presentations
Pitches from MVA Oncology Network organizations

Albin Jakobsson, CTO, Cellevate

Liselotte Nilsson, Head of Marketing, Phase Holographic, Phase Holographic

Mikkel Pedersen, SVP and Acting Chief Scientific Officer, Symphogen 

Anne-Sofie Andersson-Ward, Clinical Partnerships Manager Nordics, Kaiku Health

18:20-18:50

The future of oncology: treatments in multiple combinations.

  • AbbVie Clinical development & collaboration in oncology research – Karin Madsen, Medical Director, AbbVie 

  • Outcomes in combination trials: response, minimal residual disease, immune dysfunction, toxicity? – Carsten Utoft Niemann, Overlæge/Consultant at Department of Hematology, Rigshospitalet     

  • Patient perspectives to consider in clinical trials – Lise-lott Eriksson, Chairman of Blodcancerförbundet

18:50-19:20

Panel discussion

Moderator: Linn Mandahl, General Manager, AbbVie Scandinavia

19:20

Concluding remarks

19:30-20:00

Networking and refreshments

 Host
 

 

Sponsor 

 

 

 

MVA Oncology Network is managed by

 

In collaboration with